Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
Study reached primary and secondary endpoints of safety and immunogenicity, respectivelyVXA-CoV2-1 induced potent CD8+ T-cell responsesVXA-CoV2-1 potentially protective against new...